Eli Lilly and Company (LLY) Set to Launch Oral Obesity Drug in Q2, Reuters Reports

Reuters reported on March 2 that Eli Lilly and Company (NYSE:LLY) CFO ‌Lucas Montarce stated that the company is making preparations to launch its new oral obesity drug, orforglipron, in the United ​States as early as the second quarter of ​this year once it gets approval from the ⁠Food and Drug Administration.

The company further stated that the review is in progress as expected, and “nothing has changed” in its confidence that a decision will be made by the FDA as early as Q2. Eli Lilly and Company (NYSE:LLY) had previously stated that it has $1.5 billion worth of pre-launch inventory of its pill. In addition, Montarce stated that ‌it ⁠can begin shipping the pill within about a week after approval, facilitating a quick rollout to U.S. patients. Montarce also said at the TD Cowen healthcare conference that:

"On track in the US, ​expect to see potentially that product coming into ​the market as early as Q2".

In a separate development, Eli Lilly and Company (NYSE:LLY) announced on March 5 the launch of its Employer Connect platform, introducing new options to help in closing the access gap in U.S. obesity care. The platform expands choice, allowing coordination between employers and independent program administrators for the development of flexible and transparent solutions that support employee access to obesity management medicines.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey on Google News.